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In this paper, the authors provide estimates of 4 measures of vaccine efﬁcacy for live, attenuated and inactivated
inﬂuenza vaccine based on secondary analysis of 5 experimental inﬂuenza challenge studies in seronegative
adults and community-based vaccine trials. The 4 vaccine efﬁcacy measures are for susceptibility (VES), symp-
tomatic illness given infection (VEP), infection and illness (VESP), and infectiousness (VEI). The authors also
propose a combined (VEC) measure of the reduction in transmission in the entire population based on all of the
above efﬁcacy measures. Live inﬂuenza vaccine and inactivated vaccine provided similar protection against
laboratory-conﬁrmed infection (for live vaccine: VES ¼ 41%, 95% conﬁdence interval (CI): 15, 66; for inactivated
vaccine: VES ¼ 43%, 95% CI: 8, 79). Live vaccine had a higher efﬁcacy for illness given infection (VEP ¼ 67%,
95% CI: 24, 100) than inactivated vaccine (VEP ¼ 29%, 95% CI:  19, 76), although the difference was not
statistically signiﬁcant. VESP for the live vaccine was higher than for the inactivated vaccine. VEI estimates were
particularly low for these inﬂuenza vaccines. VESP and VEC can remain high for both vaccines, even when VEI is
relatively low, as long as the other 2 measures of vaccine efﬁcacy are relatively high.
communicable disease control; immunization; inﬂuenza, human; inﬂuenza vaccines; models, theoretical; research
design
Abbreviations: AR, attack rate; CI, conﬁdence interval; RR, relative risk; VE, vaccine efﬁcacy; VEC, combined vaccine efﬁcacy;
VEI, vaccine efﬁcacy for infectiousness; VEP, vaccine efﬁcacy for illness given infection; VES, vaccine efﬁcacy for susceptibility;
VESP, vaccine efﬁcacy for infection-conﬁrmed inﬂuenza illness.
A single measure of vaccine efﬁcacy fails to capture the
multidimensional protective effect of vaccination. Individual
vaccination can prevent or reduce a number of outcomes,
including laboratory-conﬁrmed infection, symptomatic illness
given infection, infectivity of infected individuals, or a com-
bination of these. Vaccine efﬁcacy (VE) is a measure of rel-
ative risk (RR) that generally takes the form VE ¼ 1   RR.
The absolute efﬁcacy of a vaccine compares relative risk in
a vaccinated group with that in a control group. For the rela-
tive efﬁcacy of one vaccine compared with another formu-
lated against the same infectious agent, the relative risk is
compared between 2 different groups receiving the 2 different
vaccines against the same pathogen (refer to the Appendix).
Previously, Halloran et al. (1) deﬁned several key vaccine
efﬁcacy parameters necessary to evaluate the ability of a vac-
cine to reduce infection, symptomatic illness, and infectivity.
Both vaccine efﬁcacy for susceptibility (VES)a n dv a c c i n e
efﬁcacy for infection-conﬁrmed symptomatic illness (VESP)
are unconditional measures; that is, they are not conditional
upon infection. Both take the form VE ¼ 1   AR1/AR2,
where AR1 and AR2 are the attack rates (ARs) in the
2 comparison groups for infection in the estimation of
VES or infection-conﬁrmed symptomatic illness in the esti-
mation of VESP.V E SP is often the only efﬁcacy measure
reported by phase III community-based vaccine trials, al-
though this terminology is not always applied.
Vaccine efﬁcacy for illness given infection (VEP) and
vaccine efﬁcacy for infectiousness (VEI) are both measures
in individuals who are already infected. VEP estimates the
degree to which the vaccine prevents an infected individual
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1343 Am J Epidemiol 2008;168:1343–1352from developing symptomatic illness, or the degree towhich
it successfully reduces the severity of symptoms among in-
fected individuals. Here, we are interested in pathogenicity,
which is the probability of illness given infection. We as-
sume a multiplicative relation between VES and VEP with
respect to VESP.V E I estimates the reduction in the proba-
bility that an infected, vaccinated person compared with an
infected, unvaccinated person will infect another person (1).
Currently, both inactivated inﬂuenza vaccine and live,
attenuated inﬂuenza vaccine are administered in the United
Statesyearlytoreducethe morbidityandmortalityassociated
with seasonal inﬂuenza. Yet, there is a need to estimate the
multidimensional measures of vaccine efﬁcacy described
for both of these inﬂuenza vaccines.
In this paper, we estimate VES,V E P,V E SP, and VEI for
the absolute efﬁcacy of live, attenuated vaccine; for the
absolute efﬁcacy of inactivated vaccine; and for the relative
efﬁcacy of the 2 vaccines by using data from experimental
inﬂuenza challenge studies. In addition, we categorize vac-
cine efﬁcacy estimates reported by a number of community-
based inﬂuenza vaccine trials and summarize the results
based on each of the 4 measures of vaccine efﬁcacy. Finally,
we propose the relation between VES,V E P,V E SP, and VEI
in a composite measure VEC, a measure of the reduction in
transmission in the entire population.
MATERIALS AND METHODS
Challenge study identiﬁcation
To identify recent, relevant inﬂuenza challenge studies,
we conducted a search of publications indexed in PubMed
(National Library of Medicine, National Institutes of Health,
Bethesda, Maryland). The search criteria consisted of the
following terms: (inﬂuenza, human and inﬂuenza vaccine)
and (experiment* or challenge* or ‘‘wild type’’ or wildtype).
We limited the search to articles published in English be-
tween January 1, 1980, and January 1, 2008, and indexed as
research conducted in humans to obtain results. A total
of 231 articles were returned in early 2008. In addition,
inﬂuenza experts were consulted to seek out any additional
inﬂuenza challenge studies.
To be included in this analysis, studies had to be random-
ized, controlled trials involving an experimental inﬂuenza
challenge in human subjects. At least 2 of the following
groups were required for comparison: 1) participants receiv-
ing live, attenuated inﬂuenza vaccine; 2) participants receiv-
ing inactivated inﬂuenza vaccine; and 3) controls receiving
placebo or no vaccine at all. All study participants had to be
seronegative for the inﬂuenza challenge strain (deﬁned as
serum hemagglutination-inhibition antibody titer of  1:8)
prior to vaccination. If not all participants were seronega-
tive, data for a seronegative subgroup had to be available.
The dosage of live vaccine had to exceed 10
7 50% tissue
culture infectious dose, the level used in licensed live vac-
cine. The challenge had to occur at least 2 weeks postvac-
cination, and the type of challenge strain and type of vaccine
strain administered had to be identiﬁed. Furthermore, we
required that the challenge strain be a wild-type virus (not
a vaccine strain) to more closely resemble natural infection.
The data presented had to include the outcomes of interest
(laboratory-conﬁrmed inﬂuenza infection, viral shedding,
and/or any inﬂuenza-like illness among infecteds) and pro-
vide enough detail to be able to estimate thevaccine efﬁcacy
parameters included in this secondary analysis. Each of 231
abstracts was reviewed to determine whether the inclusion
criteria were met. The full-text articles for all abstracts that
appeared to describe an inﬂuenza challenge study were then
reviewed in detail. Any uncertainties about whether a study
qualiﬁed were discussed by 2 of the authors and were re-
solved. In total, 5 studies met all of the inclusion criteria and
were included in this analysis (2–6). For 1 study (6), a subset
of the data reported in the manuscript that contained only
seronegative volunteers was analyzed in accordance with
the inclusion criteria.
Secondary analysis of challenge studies
Information about the sample size, treatment groups, type
of inﬂuenza vaccine strain, type of inﬂuenza challenge
strain, challenge strain dose, and time between vaccination
and challenge was abstracted from each article, along with
the number of participants in each treatment group for each
ofthe outcomes. Withthese data,we calculatedthe following:
1) the absolute efﬁcacy of live, attenuated vaccine; 2) the
absolute efﬁcacy of inactivated vaccine; and 3) the relative
efﬁcacy of live, attenuated vaccine compared with inacti-
vated vaccine for each of the 4 vaccine efﬁcacy measures
described above (VES,V E P,V E SP, and VEI).
To estimate VES and VESP, the formula VE ¼ 1   RR
was adapted so that the relativerisk estimate pertained to the
speciﬁc outcome of interest for each efﬁcacy measure. For
VES, infection was deﬁned as laboratory-conﬁrmed inﬂu-
enza infection, speciﬁcally evidenced by shedding of wild-
type virus on any day postchallenge, at least a 4-fold rise in
hemagglutination-inhibition antibody, or both. To estimate
VESP, the outcome was deﬁned as both laboratory-conﬁrmed
inﬂuenza infection and any illness consistent with inﬂuenza-
like symptoms. To calculate VEP ¼ 1   (relative pathoge-
nicity), the outcome was deﬁned as any illness consistent
with inﬂuenza-like symptoms in those with laboratory-
conﬁrmed inﬂuenza infection postchallenge. For VEI ¼ 1  
(relative infectiousness), the ability of an infected individual
to transmit infection was based on a surrogate measure,
namely, the presence of viral shedding on any day postchal-
lenge. All vaccine efﬁcacy estimates are presented here as
percentages.
Because the upper bound for positive efﬁcacy estimates is
1 but the lower bound for negative efﬁcacies is  N, each of
the negative efﬁcacy estimates was corrected. In the equa-
tion VE ¼ 1   RR, the reciprocal of the relative risk was
used in place of the relative risk, and the resulting difference
was multiplied by ( 1). To summarize the individual vac-
cine efﬁcacy estimates, we calculated weighted averages for
each efﬁcacy measure by using the inverse of thevariance as
the value of the weight. In addition, 95% conﬁdence inter-
vals weighted by the inverse of thevariance for each of these
summary measures were calculated by using large-sample
asymptotic methods.
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We reviewed the literature to identify several recent
community-based inﬂuenza vaccine trials that used culture-
or serologically conﬁrmed inﬂuenza outcomes or validation
sets to report at least 1 measure of vaccine efﬁcacy. We
categorized each reported measure of vaccine efﬁcacy from
the 11 studies identiﬁed according to the speciﬁc measure of
efﬁcacytowhichitcorrespondedonthebasisoftheoutcomes
that the study recorded. A brief summary of these studies is
presented in this paper.
Combined vaccine efﬁcacy
We develop the composite vaccine efﬁcacy measure, VEC,
similar to Halloran et al. (7), that measures how all the vac-
cine effects—VES,V E P,V E SP,a n dV E I—combine toreduce
transmission in the entire population (refer to the Appendix).
In a fully susceptible population, a typical infected person
will on average infect R0 other people, where R0 is the basic
reproductive number. In a population, with a fraction f of the
populationvaccinated, a typical infected person will infecton
average Rf other people, where Rf is the reproductive number
with a fraction f of the population vaccinated. Rf is given in
equation 7 in the Appendix. R1 is deﬁned as the reproductive
number if the entire population is vaccinated. We deﬁne the
combined efﬁcacy as VEC ¼ 1   (R1/R0). The form of VEC
is given in equation 9 in the Appendix. Halloran et al. (7)
previously referred to 1   VEC as the immunologically naı¨ve
equivalent, the fraction that a typical vaccinated person con-
tributes to R1 compared with an unvaccinated person to R0.
In the calculations of VEC and R1 in the results, we assume
that the pathogenicity is 67%, that is, k ¼ 0.67 (8–10). In
addition, we assume that unvaccinated, asymptomatic, in-
fected people are half as infectious as symptomatic, infected
people, that is, m ¼ 0.5 (refer to the Appendix) (9, 10).
RESULTS
Vaccine efﬁcacy estimates from inﬂuenza challenge
studies
The treatment groups available for comparison (including
the type of inﬂuenza vaccine strain), the data for each out-
come, the challenge dose, and the time interval between
vaccination and challenge are provided in Table 1 for each
of the studies analyzed. All studies identiﬁed were carried
out among adult volunteers. In each study, participants were
challenged with a wild-type strain of inﬂuenza virus homol-
ogous to 1 of the strains contained in the vaccine that they
had received. The time between vaccination and challenge
ranged from 4 weeks to 7 months.
Figure 1A–C presents both the point estimates for VES,
VEP,V E SP, and VEI and the weighted mean efﬁcacies de-
rived from each study for the absolute efﬁcacy of live vac-
cine, the absolute efﬁcacy of inactivated vaccine, and the
relative efﬁcacy of the 2 vaccines. In addition, the weighted
summary vaccine efﬁcacy point estimates and 95% conﬁ-
dence intervals are provided in Table 2.
The VES point estimates for the absolute efﬁcacy of live
(VES ¼ 41%, 95% conﬁdence interval (CI): 15, 66) and
inactivated (VES ¼ 43%, 95% CI: 8, 79) vaccine were very
similar, indicating that, on average, both vaccines offered
a comparable level of protection against laboratory-
conﬁrmed inﬂuenza infection.
The VEP for the absolute efﬁcacy of live vaccine was
VEP ¼ 67%, 95% CI: 24, 100, and the VEP for the absolute
efﬁcacy of the inactivated vaccinewas VEP ¼ 29%, 95% CI:
 19, 76. The point estimate for VEP of the live vaccine was
higher than the estimate for the inactivated vaccine, although
the conﬁdence intervals were wide and overlapping.
Live vaccine appeared to offer modestly better protection
againstlaboratory-conﬁrmedinﬂuenzaillness (VESP ¼ 77%,
95% CI: 27, 100) when compared with a control group than
inactivated inﬂuenza vaccine did (VESP ¼ 63%, 95% CI:
11, 100). However, the conﬁdence intervals were again wide
and overlapping.
The point estimates for the absolute efﬁcacy of the vac-
cine in reducing viral shedding (VEI) were low for both live,
attenuated vaccine (VEI ¼  1%, 95% CI:  27, 25) and
inactivated vaccine (VEI ¼  15%, 95% CI:  51, 20).
The point estimates for the relative efﬁcacy against infec-
tion, illness given infection, laboratory-conﬁrmed inﬂuenza
illness, and infectivity of live vaccine compared with inac-
tivated vaccine were all positive, indicating a trend toward
better protection provided by the live vaccine, although the
conﬁdence intervals lacked precision (Table 2, column 3).
Categorizing vaccine efﬁcacy estimates from
community-based inﬂuenza vaccine trials
Community-based vaccine trials often report various mea-
suresofvaccineefﬁcacydependinguponthespeciﬁcoutcome
identiﬁed in the study, whether it is laboratory-conﬁrmed
infection, illness given infection, laboratory-conﬁrmed inﬂu-
enza illness, or infectivity among infecteds. In this paper, we
categorizecommunity-basedvaccine efﬁcacy studies based on
the speciﬁc component of vaccine efﬁcacy that was reported:
VES,V E P,V E SP,V E I. All but 1 of the studies reviewed here
provided VESP estimates. The type of circulating strain was
categorized as homologous if the authors indicated that the
strainwas antigenically similar, well matched,or homologous.
The type of circulating strain was categorized as heterologous
if the authors reported that the strain was antigenically drifted
or poorly matched for some other reason. Findings are sum-
marized brieﬂy, and informative comparisons between studies
are highlighted.
Efﬁcacy against homologous inﬂuenza strains in
children
Evidence from community-based vaccine trials indicates
that live, attenuated vaccine provides signiﬁcantly better pro-
tection than inactivated vaccine against laboratory-conﬁrmed
inﬂuenza illness in children. In a randomized, double-blind
comparison of live, attenuated and inactivated vaccine admin-
istered to 7,852 children aged 6–59 months during the 2004–
2005 ﬂu season, when 1 of the circulating inﬂuenza strains
was homologous to the vaccine strain, VESP for the relative
efﬁcacy of live compared with inactivated vaccine against
culture-conﬁrmed inﬂuenza-like illness was 45% (95% CI:
Estimating Inﬂuenza Vaccine Efﬁcacy 1345
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randomized, double-blind trial among 2,187 children aged
6–71 months with a history of recurrent respiratory infections
reported similar results when the circulating inﬂuenza strain
was also homologous to the vaccine strain (VESP ¼ 53%,
95% CI: 22, 72) (12).
Several studies also reported a high VESP for the absolute
efﬁcacyoflivevaccinein children.Ananalysisofthe double-
blind, randomized controlled trial conducted among 1,602
children aged 15–71 months by Belshe et al. (13, 14) found
that the VESP for the absolute efﬁcacy of live vaccine was
92% (95% CI: 89, 94). In a double-blind, randomized con-
trolled trial of 1,616 children aged 6 to less than 36 months,
Vesikari et al. (15) reported a VESP for the absolute efﬁcacy
of live vaccine as 85% (95% CI: 74, 92). Another double-
blind, randomized controlled vaccine trial of 3,174 infants and
young children found that the efﬁcacy of live vaccine against
homologous strains was similar (VESP ¼ 73%, 95% CI: 63,
81) (16). In a community-based, nonrandomized ﬁeld trial
using surveillance cultures to estimate VESP for the absolute
efﬁcacy of live vaccine in children aged 18 months to 18
years, Halloran et al. (17) reported an efﬁcacy of 79% (95%
CI: 51, 91) against homologous strains of inﬂuenza.
Efﬁcacy against heterologous inﬂuenza strains in
children
In general, trials reporting vaccine efﬁcacies for circulat-
ing inﬂuenza strains heterologous to the vaccine strains pro-
vided lower estimates than those reporting efﬁcacy estimates
against homologous strains. Two of the studies reported the
absolute efﬁcacy of live vaccine against heterologous strains.
One study reported the absolute efﬁcacy of live vaccine
against antigenically dissimilar strains as VESP ¼ 48%,
95% CI:  11, 76 (16), and 1 reported a VESP of 66%
(95% CI: 9, 87) (17). In a community-based, nonrandom-
ized ﬁeld study of live, attenuated inﬂuenza vaccine in chil-
drenaged5–18years during the 2003–2004 inﬂuenza season,
when a drifted strain was circulating, the authors used sur-
veillance cultures to estimate efﬁcacy and reported a VESP
of 56% (95% CI: 32, 75) for the absolute efﬁcacy for live
vaccine (18).
Table 1. Data From the Experimental Inﬂuenza Challenge Studies Used in the Analysis of Inﬂuenza Vaccine
Efﬁcacy
First Author,
Year
(Reference No.)
Treatment Group
(Inﬂuenza Strain)
Total
No.
No.
Infected
No. With
Symptomatic
Illness
No. With
Viral
Shedding
Time to Challenge,
Challenge Dose
Clements,
1984 (2)
1. Live vaccine (H3N2) 16 3 0 2 5–8 weeks,
10
6.0 TCID50 2. Inactivated vaccine (H3N2) 16 10 2 10
3. Unvaccinated controls (H3N2) 24 23 11 20
Clements,
1986 (3)
1. Live vaccine (H3N2) 16 11 2 11 7 months,
10
6.0 TCID50 (H3N3),
10
4.0 TCID50 (H1N1) 2. Inactivated vaccine (H3N2) 16 11 1 11
3. Unvaccinated controls (H3N2) 27 25 12 22
4. Live vaccine (H1N1) 14 7 4 6
5. Inactivated vaccine (H1N1) 18 12 6 12
6. Unvaccinated controls (H1N1) 15 11 6 11
Sears,
1988 (4)
1. Live vaccine (H1N1) 20 12 1 6 5–7 weeks,
10
6.4 TCID50 (H1N1),
10
7.0 TCID50 (H3N2) 2. Inactivated vaccine (H1N1) 16 7 1 7
3. Unvaccinated controls (H1N1) 28 26 12 23
4. Live vaccine (H3N2) 11 5 0 5
5. Unvaccinated controls (H3N2) 10 10 3 10
Clements,
1990 (5)
1. Live vaccine (B) 13 9 0 9 6 weeks,
10
7 TCID50 2. Unvaccinated controls (B) 12 10 5 8
Treanor,
1999 (6)
1. Live vaccine (H1N1) 10 3 1 3 4 weeks,
10
7 TCID50 2. Inactivated vaccine (H1N1) 10 2 2 2
3. Placebo (H1N1) 12 7 6 6
4. Live vaccine (H3N2) 8 4 1 3
5. Inactivated vaccine (H3N2) 10 3 2 3
6. Placebo (H3N2) 4 3 3 1
7. Live vaccine (B) 7 2 0 1
8. Inactivated vaccine (B) 7 0 0 0
9. Placebo (B) 8 5 3 2
Abbreviation: TCID50, 50% tissue culture infectious dose.
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heterologous strains were low, however. A double-blind,
randomized controlled trial of 1,358 children aged 26–85
months reported a VESP for the absolute efﬁcacy of live
vaccine against heterologous strains as 89% (95% CI: 81,
94) (14, 19), which was similar to the efﬁcacy against homol-
ogous strains discussed above (14). In a randomized, double-
blind comparison of live, attenuated vaccine with inactivated
vaccine in children, the authors reported a relative efﬁcacy
against culture-conﬁrmed inﬂuenza illness caused by poorly
matched strains that was higher than that estimated for well-
matched strains (VESP ¼ 58%, 95% CI: 47, 67) (11).
Other vaccine efﬁcacy estimates in children
At r u ee s t i m a t eo fV E I is difﬁcult to obtain; as a result, VEI
is often estimated by using surrogate measures such as viral
shedding. It is not known how well such a measure reﬂects
true infectiousness in infected individuals. In an attenuated
vaccine-strain challenge study in children, the authors re-
ported a VEI for the absolute efﬁcacy of live, attenuated
vaccine as 83% (95% CI: 60, 93) using viral shedding as
a surrogate outcome (20). This value is likely to be an over-
estimate of the true VEI because an attenuated vaccine strain
was used in the challenge.
Efﬁcacy against heterologous inﬂuenza strains in
adults
Fewerrecentstudieshavereportedtheefﬁcacyofinﬂuenza
vaccineinadults.Inacommunity-basedtrialof1,247healthy
adults randomized to receive live, attenuated vaccine, inacti-
vated vaccine, or placebo during the 2004–2005 inﬂuenza
season, when a drifted strain was circulating, Ohmit et al.
(21) estimated the VESPagainst culture- or serologically con-
ﬁrmed infection and illness for the absolute efﬁcacy of inac-
tivated vaccine as 67% (95% CI: 16, 87) and for the absolute
efﬁcacy of live vaccine as 30% (95% CI:  57, 67).
As would be expected, the sensitivity of the laboratory
methodology used to conﬁrm infection affects the estimates
of vaccine efﬁcacy. In addition to reporting the vaccine ef-
ﬁcacy against culture- or serologically conﬁrmed inﬂuenza
illness, Ohmit et al. (21) also reported the efﬁcacy of live
and inactivated vaccine against culture-positive, polymerase
chain reaction–positive, culture- or polymerase chain reaction–
positive, and serologically positive infection and illness. The
estimates for the absolute efﬁcacy (VESP) of live vaccine
ranged from 28% (95% CI:  67, 67) to 57% (95% CI:  3,
82). The estimates for the absolute efﬁcacy (VESP) of inac-
tivated vaccine ranged from 74% (95% CI: 37, 89) to 78%
(95% CI: 37, 93) when based on these additional laboratory
measures (21).
Composite measure of vaccine efﬁcacy
Figure 2A shows the contour lines for values of VESP as
a function of VES and VEP. Note that different pairs of
values of VES and VEP can give rise to the same value of
VESP. However, the roles of VES and VEP are very different,
as Figure 2B–D shows. Figure 2B gives the combined vac-
cine efﬁcacy VEC as a function of VEI for different pairs of
values of VES and VEP. Observe that, for low values of VEI,
the combined efﬁcacy remains fairly high provided that
the value of VES is high or the values of both parameters
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Figure 1. Point estimates and the weighted mean for the A) absolute
efﬁcacy of live inﬂuenza vaccine based on secondary analysis of the
inﬂuenza challenge study data, B) absolute efﬁcacy of inactivated in-
ﬂuenza vaccine based on secondary analysis of the inﬂuenza chal-
lenge study data, and C) relative efﬁcacy of live versus inactivated
inﬂuenza vaccine based on secondary analysis of the inﬂuenza chal-
lenge study data. VEI, vaccine efﬁcacy for infection; VEP,v a c c i n ee f ﬁ -
cacy for illness given infection; VES, vaccine efﬁcacy for susceptibility;
VESP, vaccine efﬁcacy for laboratory-conﬁrmed inﬂuenza illness.
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D presents the combined vaccine efﬁcacy as a function of
VES and VEP, respectively, both with VEI ¼ 20%. Note that
the combined efﬁcacy is not symmetric with respect to VES
and VEP. In fact, for high values of VES, regardless of the
value of VEP, the combined vaccine efﬁcacy remains quite
high. For example, when VES ¼ 80% and VEP ¼ 20% (i.e.,
VESP ¼ 84%; refer to Figure 2A), we obtain a combined
efﬁcacy of 85%. However, for low values of VES and high
values of VEP, the combined efﬁcacy can be quite low. For
example,ifVEP ¼ 80%andVES ¼ 20%(i.e.,VESP ¼ 84%),
then the combined efﬁcacy is 56%. According to the infor-
mation presented in this paper, VES tends to range around
40% and VEP in the 30%–70% range. This puts VESP in
Table 2. Weighted Mean Vaccine Efﬁcacy Estimates and 95% Conﬁdence Intervals From
a Secondary Analysis of 5 Experimental Inﬂuenza Challenge Studies in Adults
a
Live Vaccine:
Absolute Efﬁcacy
Inactivated Vaccine:
Absolute Efﬁcacy
Live vs. Inactivated
Vaccine:
Relative Efﬁcacy
Weighted
Mean % 95% CI Weighted
Mean % 95% CI Weighted
Mean % 95% CI
VES 41 15, 66 43 8, 79 1  41, 43
VEP 67 24, 100 29  19, 76 31  47, 100
VESP 77 27, 100 63 11, 100 27  73, 100
VEI  1  27, 25  15  51, 20 20  15, 54
Abbreviations: CI, conﬁdence interval; VEI, vaccine efﬁcacy for infectiousness; VEP, vaccine
efﬁcacy for illness given infection; VES, vaccine efﬁcacy for susceptibility; VESP, vaccine efﬁcacy
for infection-conﬁrmed inﬂuenza illness.
a The 5 experimental inﬂuenza challenge studies (2–6) are described in detail in Table 1.
Figure2. Vaccineefﬁcacyfor laboratory-conﬁrmedinﬂuenzaillness(VESP) andcombinedvaccineefﬁcacy(VEC) asfunctionsof vaccineefﬁcacy
for susceptibility (VES), vaccine efﬁcacy for illness given infection (VEP), and vaccine efﬁcacy for infectiousness (VEI). A) The curves are contours
for the VESP as a function of VES and VEP. Note that the value of the VESP is constant along the contour curves at the value shown; B) VEC as
a function of VEI for different pairs of values of VES and VEP;C )V E C as a function of VES for different values of VEP when VEI is held constant at
20%;D) VEC asafunctionof VEPfor differentvaluesofVES whenVEI isheldconstantat 20%.It wasassumedthatthepathogenicity is67%,thatis,
k ¼ 0.67 (8–10) and that unvaccinated, asymptomatic, infected people are half as infectious as symptomatic, infected people, that is, m ¼ 0.5
(9, 10) (refer to the Appendix).
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range, even with modest values of VEI.
Table 3 gives our expected vaccine efﬁcacies for live and
inactivated seasonal inﬂuenza vaccine in seasons when ho-
mologous and heterologous strains are circulating based on
our best guesses from the information presented in this paper.
We used the relative efﬁcacy with VESP ¼ 50% when com-
paring live with inactivated vaccine. We assumed that VES
would be the same for live and inactivated vaccine. Then,
VEP was calculated by using the relation VESP ¼ 1   (1  
VES)(1   VEP). Because all of the point estimates for the
relative efﬁcacy for VEI in the challenge studies were non-
negative and the mean was 20%, we assumed that VEI for
the live vaccine would be somewhat higher than that for the
inactivated vaccine.
DISCUSSION
This analysis demonstrates the feasibility of estimating 4
components of vaccine efﬁcacy simultaneously by using
existing inﬂuenza challenge study data. Detailed, accurate,
and reliable outcome data are needed to calculate these
measures of vaccine efﬁcacy with precision, and steps should
be taken to incorporate the necessary data collection into the
design of vaccine ﬁeld trials, as noted before (1). In addition,
ourclassiﬁcationofvaccineefﬁcacymeasuresfromcommunity-
based vaccine trials highlights additional ranges of efﬁ-
cacy estimates observed and the importance of specifying
the exact component of vaccine efﬁcacy that is being
reported, both to assess comparability between studies
and to facilitate a more thorough understanding of the
components of vaccine efﬁcacy.
We do not know of any community-based inﬂuenza vac-
cine trial that has provided estimates of all 4 vaccine efﬁ-
cacy components or of VEI. It would be beneﬁcial to design
future phase III vaccine trials and phase IV vaccine studies
to estimate all 4 components of vaccine efﬁcacy. Better in-
fection outcome measures could be used to separately esti-
mate VES and VEP. Inclusion of transmission groups, such
as households, in the design could enable estimation of VEI.
All 4 components of protection have been successfully esti-
mated for inﬂuenza antiviral agents from randomized house-
hold clinical trials (22). In addition, Preziosi and Halloran
(23, 24) have successfully estimated VEI and VEP for per-
tussis vaccines.
Our estimates based on challenge study data indicate that
live, attenuated inﬂuenza vaccine, as well as inactivated in-
ﬂuenza vaccine, protected against inﬂuenza infection, VES,
in seronegative adult volunteers. In addition, the point esti-
mates for the absolute efﬁcacy of live vaccine were higher
for efﬁcacy against symptomatic illness given infection,
VEP, than for the inactivated vaccine, which resulted in
a higher VESP for the live vaccine.
The challenge studies did not yield particularly useful
information for valid estimation of VEI for either of these
vaccines. Because of the difﬁculty of directly measuring the
probability that an infected individual will infect a susceptible
individual, studies such as this one often must use potential
surrogatemeasuresofinfectiousness.TheVEIestimatesdrawn
from the challenge studies may be low for this very reason.
Presence or absence of viral shedding was used as a surrogate
measure ofinfectiousness,butinformationislackingregarding
its validity as a surrogate in this context, and it is likely that the
dichotomous outcome does not fully capture an infected indi-
vidual’s ability to infect a susceptible individual. Furthermore,
viralsheddingwas acomponentofthe deﬁnitionof laboratory-
conﬁrmed infection. Because VEI is estimated for only those
with laboratory-conﬁrmed infection, these deﬁnitions overlap
signiﬁcantly. It may be that more detailed characteristics of
viral shedding, including average number of days of shedding
orpeakmeantiter,wouldprovidebetterestimatesofVEI,andit
would be beneﬁcial to explore the usefulness of these mea-
sures. Yet, in the context of these challenge studies, neither
of these outcomes would eliminate the issue stemming from
the fact that viral shedding is part of the deﬁnition of labora-
tory-conﬁrmed infection.
Overall, the combined efﬁcacy, VEC, was consistently
higher for the live vaccine when compared with the inacti-
vated vaccine. VEC can remain high for these vaccines, with
relatively low VEI as long as the other 2 measures of vaccine
efﬁcacy are relatively high.
Although these results provide signiﬁcant insight into the
speciﬁc components of vaccine efﬁcacy, more data are
needed to assess additional factors key to estimating vaccine
efﬁcacy under other conditions. By combining the informa-
tionfromthechallengestudiesandthephaseIIIcommunity-
based vaccine trials and observational studies, we ﬁnd
evidence that the VESP for the live vaccine is consistently
higher than that for inactivated vaccine in children, but not
necessarily in adults (11, 21). This disparity is probably due
to prior immunity in adults, which is not present in very
young children. The challenge studies included here were
conducted among adults with little or no prior immunity to
the challenge strain, which indicates that these results may
also be somewhat applicable to children. The effects may be
larger in children given that even adults seronegative for
speciﬁc inﬂuenza strains have had greater previous exposure
to seasonal inﬂuenza than young children have. In the event
of an inﬂuenza pandemic caused by a novel inﬂuenza strain,
everyone inthe populationshouldbe immunologicallynaı ¨ve
Table 3. Expected Absolute Vaccine Efﬁcacies (%) for Live and
Inactivated Seasonal Inﬂuenza Vaccine in Homologous and
Heterologous Seasons
Live Vaccine Inactivated Vaccine
Homologous Heterologous Homologous Heterologous
VES 40 30 40 30
VEP 83 57 67 14
VESP 90 70 80 40
VEI 50 30 40 20
VEC 83 68 78 56
Abbreviations: VEC, combined vaccine efﬁcacy; VEI, vaccine efﬁ-
cacy for infectiousness; VEP, vaccine efﬁcacy for illness given infec-
tion; VES, vaccineefﬁcacyfor susceptibility; VESP,vaccineefﬁcacyfor
infection-conﬁrmed inﬂuenza illness.
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in this analysis challenged only those adult volunteers who
were seronegative to the challenge strain, these vaccine ef-
ﬁcacy results could be applicable to a pandemic situation,
although, again, the effect may be largergiventhe novelty of
the pandemic strain.
The challenge studies all administered homologous strains
of inﬂuenza during the challenge. We were unable to identify
inﬂuenza challenge studies that met our selection criteria in
which the challenge strain was heterologous to the vaccine
strain; therefore, it was not possible to estimate efﬁcacy
measures from experimental challenge study data when the
vaccine was poorly matched for comparison. There is sig-
niﬁcant interest in estimating vaccine efﬁcacy for poorly
matched strains because the prepandemic vaccines currently
being developed will likely be poorly matched to the pan-
demic strain when a pandemic strain emerges. On the other
hand, data from community-based trials in years when
poorly matched strains of inﬂuenza circulated in the com-
munity can provide insight into how well inﬂuenza vaccines
protect against poorly matched strains.
In the absence of reliable estimates from vaccine trials,
the vaccine efﬁcacy values given in Table 3 could be used as
rough guides in planning potential vaccination strategies for
seasonal inﬂuenza in children and pandemic inﬂuenza in the
community at large. This task could be accomplished by
using mathematical models (10), a subject for further re-
search (25).
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APPENDIX
Relative efﬁcacy
We compute relative efﬁcacy by comparing the vaccine
efﬁcacy estimates for the live, attenuated vaccine with those
for the inactivated vaccine. In the case of VESP, we have
VESP1 ¼ 1–(AR 1/AR0)forthelivevaccineandVE SP2 ¼ 1 
(AR2/AR0)fortheinactivatedvaccine,whereAR1andAR2are
the illness attack rates in the 2 respective vaccine arms and
AR0 is the illness attack rate in the placebo arm if there is
one. Then, for a particular vaccine effect, the relative efﬁcacy
is VErel ¼ 1–( A R 1/AR2) ¼ 1   b. Note that VErel is deﬁned
even if there is no placebo arm. The relation between the
2v a c c i n e si sV E 1 ¼ 1   b(1   VE2). So, for example, if
b ¼ 0.5andifVE2 ¼ 0.8,thenVE1 ¼ 0.9,and,ifVE2 ¼ 0.4,
then VE1 ¼ 0.7. The same logic applies to the conditional
measures of vaccine efﬁcacy.
Combined efﬁcacy
To derive a simple, tractable expression, we assume that
people mix homogeneously. We assume that an infected
person will become symptomatic with probability k,0  k
  1, that is, pathogenicity. Furthermore, we assume that
beinginfectiousandasymptomaticwillhaveamultiplicative
effect on infectiousness in the sense that an infectious,
asymptomatic person will be relatively m times as infectious
asasymptomaticperson,where0 m 1.Weparameterize
the vaccine efﬁcacies, described in the text, as vaccine efﬁ-
cacy for susceptibility, VES ¼ 1   h, vaccine efﬁcacy for
infectiousness, VEI ¼ 1   /, and vaccine efﬁcacy for dis-
ease symptoms, conditioned on being infected, as
VEP ¼ 1   w. We assume a multiplicative model for the
vaccine efﬁcacy for symptoms and infections so that
VESP ¼ 1   hw.
We follow the format from Longini et al. (26) and Hill
and Longini (27) to derive functions of the efﬁcacy mea-
sures. We deﬁne the basic reproductive number for a given
infectious disease as the expected number of secondary in-
fections resulting from a single, typical infectious individual
in a completely susceptible population. We let r0 be the
basic reproductive number for an unvaccinated, infectious,
symptomatic individual. Then, the overall basic reproduc-
tive number, R0, for the disease is
R0 ¼ð 1   kÞmr0 þ kr0 ð1Þ
R0 ¼ð ð 1   kÞm þ kÞr0: ð2Þ
We are interested in computing the expected number of
secondary infections produced by a typical infected person
during his or her entire infectious period, at the beginning of
the epidemic. We let f be the fraction of the susceptible
population that receives vaccine; I0 and I1 are the number
of secondary unvaccinated and vaccinated cases, respec-
tively. From equation 2 and the law of total probability,
we ﬁnd that
EðI0Þ¼f ð 1   kÞð1   fÞmr0 þð 1   fÞkr0g
þ f/ð1   wkÞfmr0 þ /wkfr0g: ð3Þ
The expression in the ﬁrst set of brackets represents the
probability of being infected by an unvaccinated, infectious,
asymptomatic person (the ﬁrst summand) plus the probabil-
ity of being infected by an unvaccinated, symptomatic per-
son (the second summand).
The expression in the second set of brackets represents
the probability of being infected by a vaccinated person and
again has 2 summands, each representing an asymptomatic
and a symptomatic, vaccinated, infectious person. In both
summands, the probability of being infected is reduced by
a factor of / because of the vaccine efﬁcacy for infectious-
ness. The ﬁrst summand represents the probability of being
infected by a vaccinated, asymptomatic person. In this in-
stance, the probability that he or shewill be asymptomatic is
1 wk. The last summand represents the probability of being
infected by a vaccinated, symptomatic person, so it is
reduced by w.
Rearranging terms, we have
EðI0Þ¼r0ð1   fÞfð1   kÞm þ kg
þ r0f/fð1   wkÞm þ kwg: ð4Þ
Similarly, the number of secondary infections among the
vaccinated susceptible population is
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þ hf/ð1   wkÞfmr0 þ /wkfr0g
¼ r0hð1   fÞfð1   kÞm þ kg
þ r0h/ffð1   wkÞm þ wkg: ð5Þ
We deﬁne the next generation matrix as
Mf ¼ r0

ð1 fÞðð1 kÞmþkÞ /fðð1 wkÞmþwkÞ
hð1 fÞðð1 kÞmþkÞ h/fðð1 wkÞmþwkÞ

:
ð6Þ
Wehavegivenaheuristicderivationofthenext-generation
matrix, equation 6, but the matrix can also can be derived
from local stability analysis around the initial conditions
based on the system of differential equations for the system
by using a construction similar to that given in Hill and
Longini et al. (27); also refer to Farrington (28).
The largest eigenvalue of Mf is the reproductive number
with the fraction f of the population vaccinated, where
Rf ¼ r0fð1   fÞðð1   kÞm þ kÞþh/fðð1   wkÞm þ wkÞg:
ð7Þ
If nobody is vaccinated, that is, f ¼ 0, then Rf ¼ R0,i n
agreement with our previous deﬁnition. If Rf > 1, the epi-
demic grows, whereas, if Rf   1, the epidemic will die out.
We deﬁne the combined efﬁcacy, VEC, by examining the
reproductive number when everyone in the population is
vaccinated, that is, f ¼1, which is
R1 ¼ r0ðh/ðð1   wkÞm þ wkÞÞ: ð8Þ
Then, the combined efﬁcacy is
VEC ¼ 1  
R1
R0
¼ 1  
h/ðð1   wkÞm þ wkÞ
ð1   kÞm þ k
: ð9Þ
VEC is a useful index because it assesses the combined
effect of all 3 vaccine efﬁcacy components, that is,
VES ¼ 1   h,V E I ¼ 1   /, and VEP ¼ 1   w.
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